Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
InMed Pharmaceuticals Inc
INM | US
0.71
USD-0.00
-0.32%
INM | US
About InMed Pharmaceuticals Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
15/04/2026
Close
0.71
Open
0.72
High
0.72
Low
0.69
InMed Pharmaceuticals Inc. a clinical stage pharmaceutical company develops a pipeline of prescription-based products. The company operates through two segments the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. The company's prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. Its lead product is INM-755 a cannabinol topical skin cream which is in Phase 2 clinical trial for the treatment of epidermolysis bullosa. The company is also developing INM-088 which is in preclinical studies for the treatment of glaucoma; INM-405 for the treatment of pain; and cannabinoid-based treatments for various diseases including dermatology and ocular diseases. In addition it offers IntegraSyn an integrated biosynthesis-based manufacturing approach for pharmaceutical-grade cannabinoids; and cannabichromene cannabicitran cannabidivarin and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver Canada.
View LessINM | US
Risk
83.9
Sharpe
-0.72
Luna's Score
48/100
Recommendation
Hold
Luna says (INM | US)
What's Working
Low Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
What's not Working
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
67.9%1 month
83.9%3 months
83.1%6 months
86.3%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
0.22
Debt to equity
0.07
Debt to assets
0.05
Ent. to EBITDA
1.00
Ent. to rev.
1.47
PEG
-
Other Fundamentals
EBITDA
-7.91M
MarketCap
9.50M
MarketCap(USD)
9.50M
Div. yield
-
Op. margin
-156.58
Erngs. growth
-
Rev. growth
-44.50
Ret. on equity
-72.09
Short ratio
0.09
Short perc.
1.05
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
0.14
Range1M
0.35
Range3M
0.60
Volumes: Market Activity
Rel. volume
0.34
Price X volume
41.73K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 1.00 | - | Expensive |
| Ent. to Revenue | 1.47 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 0.22 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 83.06 | - | Par |
| Debt to Equity | 0.07 | -1.23 | Expensive |
| Debt to Assets | 0.05 | 0.25 | Cheaper |
| Market Cap | 9.50M | - | Emerging |
